Market Overview

Amylin Jumps 12% After Hiring Bankers to Advise on Sale

Shares of Amylin Pharmaceuticals (NASDAQ: AMLN) have surged roughly 12% to $25.76 on Monday after Reuters reported that the company had hired Goldman Aachs (NYSE: GS) and Credit Suisse (NYSE: CS) to act as its financial advisers in a potential sale. The company also hired Skadden Arps to provide legal advice according to Reuters. The report added that AMLN had reached out to potential buyers in the last week.

Amylin Pharmaceuticals, Inc. (Amylin) is a biopharmaceutical company focusing on the diabetes and other metabolic diseases through the discovery, development and commercialization of medicines.

Posted-In: News Rumors M&A Intraday Update Movers

 

Most Popular

Related Articles (AMLN + CS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters